{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-171148","form_type":"8-K","ticker":null,"cik":"0001044378","company_name":"BIOCEPT INC","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.748547+00:00","generated_at":"2026-06-13T19:40:13.333490+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Biocept appoints Antonino Morales as President and CEO; Riccitelli resigns","bullets":["Samuel D. Riccitelli resigned as Interim President and CEO and from Board, effective June 16, 2023.","Antonino Morales appointed President and CEO; continues as CFO and Board member.","Morales' base salary increased from $400K to $470K; target bonus raised from 40% to 50%.","Robert Walsh promoted to VP, Controller and principal accounting officer.","Walsh, a CPA, joined Biocept in May 2022; previously at PwC and CFGI."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-171148","json":"https://secwatch.observer/filing/0001193125-23-171148.json","markdown":"https://secwatch.observer/filing/0001193125-23-171148.md","text":"https://secwatch.observer/filing/0001193125-23-171148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/d524228d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:40:13.333490+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b39412ab7","claim":"Samuel D. Riccitelli resigned as Interim President and Chief Executive Officer at BIOCEPT INC.","evidence_excerpt":"On June 16, 2023, Samuel D. Riccitelli resigned from his position as Interim President and Chief Executive Officer of Biocept, Inc. (the “Company”), and from the Company’s Board of Directors (the “Board”), effective June 16, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c0baf9940d","claim":"Robert Walsh changed role as Vice President, Controller and principal accounting officer at BIOCEPT INC.","evidence_excerpt":"On June 16, 2023, Robert Walsh, the Company’s Controller, was promoted to Vice President, Controller and principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"Vice President, Controller and principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"ec3f11fa8d","claim":"Antonino Morales was appointed as President and Chief Executive Officer at BIOCEPT INC.","evidence_excerpt":"On June 16, 2023, the Board appointed Antonino Morales as the Company’s President and Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1044378/000119312523171148/0001193125-23-171148-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}